An Optimized Ultrasound Twinkling Marker for the Imaging of Lymph Nodes in Patients With Clinically Node-Positive Breast Cancer, The UTMOST2 Trial
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I trial studies the performance, including ultrasound visibility, of an optimized ultrasound twinkling marker in imaging lymph nodes in patients with clinically node-positive breast cancer. In patients with biopsy-proven breast cancer, biopsy markers are used to identify the sites of cancer involvement in both the breasts and lymph nodes. These biopsy markers are critical for guiding surgical management many months after the marker is placed. For breast radiologists and breast surgeons, there is a need for simple, consistent visibility of biopsy markers by ultrasound, particularly several months after marker placement. Ultrasound is the imaging method of choice, particularly for lymph nodes in the armpit (axilla). Ultrasound is non-ionizing and is more comfortable for patients compared to mammography. However, ultrasound visibility of these markers is challenging and inconsistent, with ultrasound failing to detect the marker approximately 25% of the time. The Mayo-designed investigational biopsy marker takes advantage of an ultrasound phenomenon called twinkling artifact. The Mayo-designed optimized ultrasound twinkling marker may work better than standard biopsy clip marker in imaging lymph nodes in patients with clinically node-positive breast cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej z rakiem piersi potwierdzonym badaniem biopsji węzła chłonnego w pachwie
- •Chirurg zdecyduje czy będzie możliwe wstępne znakowanie węzła lub usunięcie go podczas operacji przy pomocy ultrasonografu
- •Operację przeprowadzi jeden z chirurgów z Kliniki Chirurgii Nowotworów Piersi i Melanoma
- •Pacjent musi rozumieć procedury badania i być zdolny do ich wykonywania przez cały czas trwania badania
- •Antykoncepcja nie jest wymagana
✗ Disqualifies
- •Ciąża
- •Bieżące lub przeszłe uzależnienie od narkotyków lub alkoholu, które może utrudnić przestrzeganie wymagań badania
- •Uczestnictwo w innym badaniu klinicznym w ostatnim określonym czasie
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- February 12, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Mayo Clinic in Rochester
Rochester, United States
Trial contact
Clinical Trials Referral Office
Breast and Melanoma Surgical Oncology (BSMO) Clinical Research Unit
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.